Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 823-831 , October 2007

Imaging multidrug resistance with 4-[18F]fluoropaclitaxel

  • Karen A. Kurdziel

      Affiliations

    • Department of Radiology, Virginia Commonwealth University, Richmond, VA, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 804 827 4984; fax: 1 804 828 4181.
    • ,
  • Joseph D. Kalen

      Affiliations

    • School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
    • ,
  • Jerry I. Hirsch

      Affiliations

    • School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
    • ,
  • John D. Wilson

      Affiliations

    • School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
    • ,
  • Rakesh Agarwal

      Affiliations

    • Surgical Oncology, Virginia Commonwealth University, Richmond, VA, USA
    • ,
  • Daniel Barrett

      Affiliations

    • School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
    • ,
  • Harry D. Bear

      Affiliations

    • Surgical Oncology, Virginia Commonwealth University, Richmond, VA, USA
    • ,
  • James F. McCumiskey

      Affiliations

    • Department of Radiology, Virginia Commonwealth University, Richmond, VA, USA

Received 23 February 2007 ,Revised 16 April 2007 ,Accepted 17 April 2007.

References 

  1. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol. 2000;12:450–458
  2. Gottesman MM. How cancer-cells evade chemotherapy — 16th Richard-and-Hinda-Rosenthal-Foundation Award Lecture. Cancer Res. 1993;53:747–754
  3. Lum B, Gosland M. MDR expression in normal-tissues — pharmacological implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am. 1995;9:319–336
  4. Pavelic ZP, Reising J, Pavelic L, Kelley DJ, Stambrook PJ, Gluckman JL. Detection of P-glycoprotein with 4 monoclonal-antibodies in normal and tumor-tissues. Arch Otolaryngol Head Neck Surg. 1993;119:753–757
  5. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, SchmiedlinRen P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62:248–260
  6. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev. 1997;27:161–170
  7. Liang XJ, Aszalos A. Multidrug transporters as drug targets. Curr Drug Targets. 2006;7:911–921
  8. Lan LB, Ayesh S, Lyubimov E, Pashinsky I, Stein WD. Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing. Cancer Chemother Pharmacol. 1996;38:181–190
  9. Moins N, Cayre A, Chevillard S, Maublant J, Verrelle P, Finat-Duclos F. Effects of MDR reversing agent combinations on the H-3-daunomycin accumulation in drug-sensitive and drug-resistant human cancer cells. Anticancer Res. 2000;20:2617–2623
  10. Plumb JA, Wishart GC, Setanoians A, Morrison JG, Hamilton T, Bicknell SR, et al. Identification of a multidrug-resistance modulator with clinical potential by analysis of synergistic activity in-vitro, toxicity in-vivo and growth delay in a solid human tumor xenograft. Biochem Pharmacol. 1994;47:257–266
  11. Hendrikse NH, Franssen EJ, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med. 1999;26:283–293
  12. Cardarelli CO, Aksentijevich I, Pastan I, Gottesman MM. Differential-effects of P-glycoprotein inhibitors on Nih3t3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res. 1995;55:1086–1091
  13. DelVecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med. 1997;38:1348–1351
  14. Sikic B, Fisher G, Lum B, Halsey J, BeketicOreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40:S13–S19
  15. Aloj L, Del Vecchio S, Damiano M, Zannetti A, Di Gennaro F, Imbriaco F, et al. Fractional retention of 99mTc-MIBI and proliferation in untreated breast cancer. Eur J Nucl Med. 1999;26:PS455
  16. Fukumoto M, Yoshida D, Hayase N, Kurohara A, Akagi N, Yoshida S. Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma — technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study. Cancer. 1999;86:1470–1479
  17. Barbarics E, Kronauge JF, Cohen D, Davison A, Jones AG, Croop JM. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res. 1998;58:276–282
  18. Chen CC, Meadows B, Regis J, Kalafsky G, Fojo T, Carrasquillo JA, et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin. Cancer Res. 1997;3:545–552
  19. Hendrikse NH, de Vries EGE, Franssen EJF, Vaalburg W, van der Graaf WTA. In vivo measurement of [C-11] verapamil kinetics in human tissues. Eur J Clin Pharmacol. 2001;56:827–829
  20. Levchenko A, Mehta BM, Lee JB, Humm JL, Augensen F, Squire O, et al. Evaluation of C-11-colchicine for PET imaging of multiple drug resistance. J Nucl Med. 2000;41:493–501
  21. Elsinga PH, Franssen EJF, Hendrikse NH, Fluks L, Weemaes AMA, vanderGraaf WTA, et al. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med. 1996;37:1571–1575
  22. Hendrikse NH, Schinkel AH, De Vries EGE, Fluks E, Van der Graaf WTA, Willemsen ATM, et al. Complete in vivo reversal of P-glycoprotein pump function in the blood–brain barrier visualized with positron emission tomography. Br J Pharmacol. 1998;124:1413–1418
  23. Hendrikse NH, de Vries EGE, Eriks-Fluks L, van der Graaf WTA, Hospers GAP, Willemsen ATM, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood–brain barrier. Cancer Res. 1999;59:2411–2416
  24. Ravert H, Klecker R, Collins J, Mathews W, Pomper M, Wahl R, et al. Radiosynthesis of [C-11] paclitaxel. J Labelled Compd Radiopharm. 2002;45:471–477
  25. van Tilburg EW, Franssen EJF, van der Hoeven JJM, van der Meij M, Elshove D, Lammertsma AA, et al. Radiosynthesis of [C-11] docetaxel. J Labelled Compd Radiopharm. 2004;47:763–777
  26. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer. 1998;83:245–253
  27. Hohenberger P, Strauss LG, Lehner B, Frohmuller S, Dimitrakopoulou A, Schlag P. Perfusion of colorectal liver metastases and uptake of fluorouracil assessed by H2(15)O and [18F]uracil positron emission tomography (PET). Eur J Cancer. 1993;29A:1682–1686
  28. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs. 1998;9:1–17
  29. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 1997;11:253–257
  30. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659–5667
  31. Higashi K, Ueda Y, Ikeda R, Kodama Y, Guo J, Matsunari I, et al. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer. Nucl Med Commun. 2004;25:19–27
  32. Li C, Yu DF, Inoue T, Yang DJ, Tansey W, Liu CW, et al. Synthesis, biodistribution and imaging properties of indium-111–DTPA–paclitaxel in mice bearing mammary tumors. J Nucl Med. 1997;38:1042–1047
  33. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, et al. Estimation of paclitaxel biodistribution and uptakein human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med. 2005;46:1866–1871
  34. Hsueh W, Kesner A, Gangloff A, Pegram M, Beryt M, Czernin J, et al. Predicting chemotherapy response to paclitaxel with 18F-fluoropaclitaxel and PET. J Nucl Med. 2006;47:1995–1999
  35. Schinkel AH. Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther. 1998;36:9–13
  36. Jagoda E, Kiesewetter D, Shimoji K, Ravasi L, Eckelman W. Comparison of the biodistribution of fluorinated and tritiated paclitaxel (PAC) in mdr1a(−)/1b(−) knockout vs. wildtype mice. J Nucl Med. 2002;43:277P
  37. Kiesewetter D, Eckelman W. Radiochemical synthesis of [18F]fluoropaclitaxel ([18F]FPAC). J Labelled Compd Radiopharm. 2001;S903–S905
  38. Kurdziel K, Kiesewetter D, Carson R, Eckelman W, Herscovitch P. Biodistribution, radiation dose estimates and Pgp modulation studies of [18F]paclitaxel. J Nucl Med. 2001;42(S):279P
  39. Kalen JD, Hirsch JI, Kurdziel KA, Eckelman WC, Kiesewetter DO. Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]paclitaxel (FPAC). Appl Radiat Isot. 2007;65:696–700
  40. Bartsch H, Dally H, Popanda O, Risch A, Schmezer P. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res. 2007;174:19–36
  41. Mazouni C, Kau SW, Frye D, Andre F, Kuerer H, Buchholz T, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007;18:874–880
  42. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, et al. Prognostic relevance of response evaluation using [F-18]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:8362–8370
  43. Rousseau C, Ferrer L, Bridji B, Campion L, Sagan C, Ricaud M, et al. Early response monitoring by FOG-PET to neoadjuvant chemotherapy in locally advanced breast cancer patients. J Clin Oncol. 2005;23:140S
  44. Schwarz JD, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential F-18-FDG PET. J Nucl Med. 2005;46:1144–1150

PII: S0969-8051(07)00124-2

doi: 10.1016/j.nucmedbio.2007.04.011

Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 823-831 , October 2007

Article Tools

* Image Usage & Resolution